LYEL
Income statement / Annual
Last year (2024), Lyell Immunopharma, Inc.'s total revenue was $61.00 K,
a decrease of 53.08% from the previous year.
In 2024, Lyell Immunopharma, Inc.'s net income was -$342.99 M.
See Lyell Immunopharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$61.00 K |
$130.00 K |
$84.68 M |
$10.65 M |
$7.76 M |
$657.00 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$61.00 K
|
$130.00 K
|
$84.68 M
|
$10.65 M
|
$7.76 M
|
$657.00 K
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$171.60 M
|
$182.95 M
|
$159.19 M
|
$138.69 M
|
$182.24 M
|
$63.60 M
|
| General & Administrative Expenses |
$52.04 M
|
$66.98 M
|
$117.31 M
|
$89.06 M
|
$46.88 M
|
$39.15 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$52.04 M
|
$66.98 M
|
$117.31 M
|
$89.06 M
|
$46.88 M
|
$39.15 M
|
| Other Expenses |
$135.17 M
|
-$2.79 M
|
-$4.75 M
|
-$2.32 M
|
-$9.43 M
|
$0.00
|
| Operating Expenses |
$358.82 M
|
$247.14 M
|
$271.74 M
|
$225.43 M
|
$219.69 M
|
$102.75 M
|
| Cost And Expenses |
$358.82 M
|
$247.14 M
|
$271.74 M
|
$225.43 M
|
$219.69 M
|
$102.75 M
|
| Interest Income |
$24.07 M
|
$23.45 M
|
$7.05 M
|
$1.17 M
|
$5.94 M
|
$8.12 M
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$19.63 M
|
$20.25 M
|
$18.02 M
|
$13.62 M
|
$4.29 M
|
$1.26 M
|
| EBITDA |
-$200.64 M |
-$226.76 M |
-$169.04 M |
-$201.15 M |
-$215.43 M |
-$100.83 M |
| EBITDA Ratio |
-3289.23
|
-1744.29
|
-2
|
-18.89
|
-27.78
|
-153.47
|
| Operating Income Ratio |
-5881.23
|
-1900.06
|
-2.21
|
-20.17
|
-27.33
|
-155.39
|
| Total Other Income/Expenses Net |
$15.76 M
|
$12.38 M
|
$3.94 M
|
-$35.44 M
|
$7.47 M
|
-$27.29 M
|
| Income Before Tax |
-$342.99 M
|
-$234.63 M
|
-$183.12 M
|
-$250.22 M
|
-$204.47 M
|
-$129.38 M
|
| Income Before Tax Ratio |
-5622.85
|
-1804.86
|
-2.16
|
-23.49
|
-26.36
|
-196.92
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$342.99 M
|
-$234.63 M
|
-$183.12 M
|
-$250.22 M
|
-$204.47 M
|
-$129.38 M
|
| Net Income Ratio |
-5622.85
|
-1804.86
|
-2.16
|
-23.49
|
-26.36
|
-196.92
|
| EPS |
-1.31 |
-0.9348 |
-0.7411 |
-1.0308 |
-0.8438 |
-0.5293 |
| EPS Diluted |
-1.31 |
-0.9348 |
-0.7411 |
-1.0308 |
-0.8438 |
-0.5293 |
| Weighted Average Shares Out |
$261.48 M
|
$250.98 M
|
$247.08 M
|
$242.74 M
|
$246.58 M
|
$246.58 M
|
| Weighted Average Shares Out Diluted |
$261.48 M
|
$250.98 M
|
$247.08 M
|
$242.74 M
|
$246.58 M
|
$246.58 M
|
| Link |
|
|
|
|
|
|
